RESULTS: Four weeks after subcutaneous autograft of LSCs in combination with Sertoli and myoid cells in castrate mice, the cells in graft expressed 3B-HSD, SOX-9 and A-SMA. Serum testosterone in castrated mice that received autograft was significantly higher compared to mice that did not receive autograft (22.4þ/-1.9 VS 11.9þ/-0.8 Ng/DL, p<0.05). Importantly, mice that received LSC autograft maintained production of LH and FSH with levels higher than mice that received testosterone pellet implant (LH 3.09þ/-1.47 VS 0.01þ/-0.01 ng/ml) (FSH 102.6þ/-28.1 VS 51.7þ/-7.4ng/ml) respectively. Furthermore, T levels consistently increased at 15, 30 and 60 days following subcutaneous autograft (12.01þ/-0.87ng/DL (neg CTL) vs 15.1þ/-1.50ng/DL (15 days Autograft) vs 22.26þ/-1.33ng/DL (30 days Autograft) vs 37.3þ/-9.6ng/DL (60 days Autograft)), demonstrating differentiating LSC within the autograft. In addition, we found that levels of 3BHSD were induced upon SAG (DHH inducer) treatment in-vitro conditions. Immunostaining autografts (4 weeks), containing LSCs treated with SAG before subcutaneous implantation, showed higher levels of SOX9, and A-SMA. Importantly, T levels were significantly higher (p<0.05) in mice received SAG treated autografts vs negative controls (23.95þ/-4.11 Ng/DL vs 11.91þ/-0.80 Ng/DL). Collectively these results establish that Hedgehog signalling induces survival of adjacent testicular cells and regulates graft function.
INTRODUCTION AND OBJECTIVES: Beta-adrenoceptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Mirabegron is a selective beta3-adrenoceptor (ADRB3) agonist that has been approved for the treatment of overactive bladder. Studies in rats showed that mirabegron was associated with atrophy and/or reduced weights of the accessory reproductive organs, and in females, prolonged diestrus and decreased numbers of live fetuses. In this study, we evaluated the potential effects of mirabegron on the molecular expressions in rat Sertoli cell (SC) primary culture.
METHODS: SCs were purified from testes of 18-day-old Sprague-Dawley rats. Primary cultures were treated with 1mM mirabegron in the absence or presence of 10mM U0126, a selective noncompetitive inhibitor of Mitogen-Activated Protein (MAP) kinase kinase. Immunofluorescent (IF) study was performed using the primary SC culture to determine the expression of ADRB3 in rat SCs. Protein samples were extracted from whole cell homogenates. Western blot (WB) analysis was performed to explore phosphorylation of MAP kinases. Total RNA was also extracted from SCs. Quantitative real-time RT-PCR (q-PCR) analysis was conducted to determine the expression levels of tight junction related mRNAs.
RESULTS: IF study showed that ADRB3 was present in rat SCs. WB analyses showed that mirabegron treatment induced the significant activation of p44/42 MAPK. Q-PCR showed that mirabegron treatment led to significant increase in claudin-11 mRNA levels. After additional treatment with U0126, mirabegron-induced up-regulation of Claudin-11 had reduced.
CONCLUSIONS: These data suggest that ADRB3 is present in rat SCs. ADRB3 may be associated with spermatogenesis through p44/ 42 MAPK induced tight junction molecules alteration in rat SCs.
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MP60-03 SERUM METABOLOMIC ANALYSIS IDENTIFIES UNIQUE SIGNATURES IN AZOOSPERMIC MEN
Zhe Zhang*, Hui Jiang, Beijing, China, People's Republic of INTRODUCTION AND OBJECTIVES: Infertility is considered as a major health problem, and azoospermia cases due to 10% of male factors. Azoospemia is the most challenging task for andrologist, for these patients rarely can father their own genetic offspring. Therefore, it is imperative to investigate the molecular mechanism underlying idiopathic azoospermia and seek a potential treatment.
METHODS: The subjects with idiopathic azoospermia were enrolled from Reproductive Center of Peking University Third Hospital (PUTH), and healthy controls form Human Sperm Bank of PUTH. The blood samples from both idiopathic azoospermia and healthy control were used for untargeted metabolites screening by high performance liquid chromatography. All metabolites were introduced to MetaboAnalyst3.0 for data processing, PCA and OPLS-DA was performed to reduce the dimensionality of the data and to reveal any clustering in an unsupervised manner. The significance of variable was quantified by the variable importance in the project (VIP) plot of the established OPLS-DA model. Mann-Whitney U test and chi-square test. Metabolites relative content were analyzed with two-tailed Student's t-test using. Any difference with p < 0.05 was considered statistically significant.
RESULTS: A total of 22 idiopathic azoospermic patients and 31 normal controls were enrolled in the case-control sutdy. In the group of azoospermia, infertile men were identified as early/late maturation arrest, Sertoli-cell only. There is an obvious segregation of metabolomic profiles was observed in the group of azoospermic cases in PCA model. The entired data set was identified by a further supervised analysis of PLS-DA, and revealed a clearer separation of azoospermia from the fertile cases. Extracted variables that contributed the most in the case control group differentiation were chosen to be biomarkers for idiopathic azoospermic diagnosis, and acetylcarnitine, citrate, arginine and taurine were identified. The pathways had the top 5 pathway impact are: A. Alanine, aspartate and glutamate metabolism; B. Citrate cycle (TCA cycle); C. Arginine and proline metabolism; D. Butanoate metabolism; E. D-Glutamine and D-glutamate metabolism.
CONCLUSIONS: Several potential metabolites were identified that are closely associated to energy production and oxidative stress in spermatogenesis. Biosynthesis and metabolism of these metabolites may contribute to the aetiologies of idiopathic azoospermia. Our findings suggested that metabolomics fingerprinting could provide a promising screening approach to detect possible biomarkers and improve our understanding of mechasnisms underlying male infertility, and eventually aiding to etiological diagnose and therapy intervention. . 199, No. 4S, Supplement, Sunday, May 20, 2018 
